GLYC Crescent Biopharma Inc.


$ 12.80 $ 0.00 (0 %)    

Friday, 24-Oct-2025 09:46:09 EDT
QQQ $ 616.10 $ 0.15 (0.02 %)
DIA $ 470.83 $ 1.01 (0.21 %)
SPY $ 676.70 $ 0.22 (0.03 %)
TLT $ 91.22 $ -0.34 (-0.37 %)
GLD $ 377.61 $ -0.96 (-0.25 %)
$ 12.79
$ 12.95
$ 12.55 x 100
$ 12.90 x 50
-- - --
$ 9.81 - $ 63.00
83,118
na
na
$ 1.69
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 glycomimetics-merger-bound-crescent-appoints-joshua-brumm-as-ceo

Crescent also appointed Jonathan McNeill, president and chief operating officer; Ellie Im, M.D., chief medical officer; Rick Sc...

 cantor-fitzgerald-initiates-coverage-on-glycomimetics-with-overweight-rating

Cantor Fitzgerald analyst Eric Schmidt initiates coverage on GlycoMimetics (NASDAQ:GLYC) with a Overweight rating.

 glycomimetics-and-crescent-amend-merger-agreement-crescent-to-own-9690-post-merger-200m-securities-purchase-reallocated-ownership-and-exchange-ratio-unchanged-18m-net-cash-at-closing

- SEC Filing

 glycomimetics-shares-are-soaring-tuesday-heres-why

GlycoMimetics, Inc. (NASDAQ:GLYC) shares are moving higher on Tuesday after the company announced it will merge with Crescent B...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION